The latest Investing Matters Podcast episode featuring financial educator and author Jared Dillian has been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksVenn Life Sciences Share News (VENN)

  • There is currently no data for VENN

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Rightmove Chairman sells 7m pounds of shares

Tue, 27th May 2014 15:09

Rightmove's Chairman Scott Forbes has offloaded nearly a half of a holding in the property website group, selling over seven million pounds in shares.Forbes, who has been in his current role since 2005, sold 300,000 shares at an average price of 2,350.81p each, raising a total of £7.05m.Following the deal, his holding was reduced to 319,300 shares, representing a 0.3221% stake in the company.Rightmove said earlier this month that it had made a "positive start" to 2014 as audience continued to grow with page impressions up 14% in the first four months of the year.Meanwhile, the company generated a record 14.8m enquiries for its customers, up 30% on the year, while average revenues per advertiser showed "healthy growth".The business has been boosted over the past year by the recent boom in the UK housing market. However, competition has increased in recent months with rival firm Zoopla announcing its intention to float in June and another property portal called Agent Mutual due to launch next January.Rightmove's shares have fallen by around 15% in the year-to-date but have still risen by nearly 500% since the stock first listed in 2006.Top Director BuysEveryman Media Group (EMAN) Director name: Mr Adam KayeAmount purchased: 207,409 @ 89.00p Value: £184,594REA Holdings (RE.) Director name: Mr David BlackettAmount purchased: 10,000 @ 470.00p Value: £47,000Venn Life Sciences Holdings (VENN) Director name: Mr David Eric EvansAmount purchased: 210,000 @ 20.50p Value: £43,050Dunedin Enterprise Investment Trust (DNE) Director name: Mr Brian FinlaysonAmount purchased: 6,600 @ 429.78p Value: £28,365Wolf Minerals Limited (WLFE) Director name: Mr Russell Clark Amount purchased: 83,333 @ 30.00p Value: £25,000Kea Petroleum (KEA) Director name: Mr Ian Roderick Gowrie-SmithAmount purchased: 865,140 @ 1.95p Value: £16,870NWF Group (NWF) Director name: Mr Philip ActonAmount purchased: 10,000 @ 155.00p Value: £15,500Laird (LRD) Director name: Mr David LockwoodAmount purchased: 4,163 @ 283.59p Value: £11,806Top Director SellsRightmove (RMV) Director name: Mr Scott ForbesAmount sold: 300,000 @ 2,350.81p Value: £7,052,430Grafton Group Units (GFTU) Director name: Mr Gavin SlarkAmount sold: 41,700 @ 585.00p Value: £243,945Hansa Trust 'A' Non Voting Shares (HANA) Director name: Professor Geoffrey WoodAmount sold: 6,500 @ 960.00p Value: £62,400Hansa Trust (HAN) Director name: Professor Geoffrey WoodAmount sold: 5,000 @ 952.00p Value: £47,600Dunedin Enterprise Investment Trust (DNE) Director name: Mr Brian FinlaysonAmount sold: 5,975 @ 475.00p Value: £28,381BC
More News
18 Nov 2016 09:38

Venn Life Sciences completes £4.74m Innovenn sale

(ShareCast News) - Drug trial company Venn Life Sciences has completed the sale of its stake in Innovenn UK innovation unit to Integumen for up to £4.74m that will see it retain a majority stake as the newly created skin science company looks to float on AIM. Integumen has been set up by Venn's dire

Read more
8 Nov 2016 09:31

Venn Life Sciences wins new contract worth EUR2.5m

(ShareCast News) - Venn Life Sciences has signed a new contract worth €2.5m with Sedana Medical for a phase III trial. The trial, which is confined to patients in Germany and commences immediately, will confirm the efficacy and safety of sedation with isoflurane in ventilated intensive care patients

Read more
2 Nov 2016 16:13

Director dealings: Venn Life Sciences chairman sees value

(ShareCast News) - Venn Life Sciences chairman Allan Wood bought £50,000 worth of the contract clinical research provider's shares, it was revealed on Wednesday. Wood picked up 230,000 shares in two purchases at an average price of 21.67p. Shares in the AIM-listed company have drifted since interim

Read more
27 Oct 2016 14:26

Venn Life Sciences shareholders approve sale of Innovenn UK

(ShareCast News) - Drug development and clinical trial management contract research organisation Venn Life Sciences confirmed on Thursday that its shareholders had approved of a deal to offload Innovenn UK. The AIM-traded company had announced on 4 October that its wholly owned subsidiary, Venn Life

Read more
4 Oct 2016 14:33

Venn Life Sciences to offload Innovenn UK

(ShareCast News) - Contract research organisation Venn Life Sciences announced on Tuesday that its wholly owned subsidiary, Venn Life Sciences Limited, has entered into a conditional agreement under which it and Lynchwood Nominees Limited, as custodian for the Helium Rising Stars Fund, would sell th

Read more
28 Sep 2016 11:21

Venn Life Sciences shares drop despite revenue rise

(ShareCast News) - Drug development services and clinical trial management provider Venn Life Sciences announced its unaudited interim results for the six months to 30 June on Wednesday, with revenue of €9.06m, up from €4.25m in the first half of last year. The AIM-traded firm had EBITDA profit of €

Read more
3 Aug 2016 14:07

Venn Life Sciences wins €2.8m contract

(ShareCast News) - Contract research organisation Venn Life Sciences said it has signed a new contract worth €2.8m with an unnamed European biotechnology client. Venn, which provides drug development, clinical trial management and resourcing solutions to pharmaceutical, biotechnology and medical dev

Read more
30 Jun 2016 07:38

Venn Life Sciences On Track To Swing To Profit In Full Year

Read more
23 Jun 2016 15:08

UK Shareholder Meetings Calendar - Next 7 Days

Read more
10 May 2016 07:56

Venn Life Sciences Loss Narrows As Revenue More Than Doubles

Read more
3 May 2016 15:16

Earnings, Trading Statements Calendar - Week Ahead

Read more
24 Mar 2016 08:30

Venn Life Sciences Says 2015 Revenue To Beat Market Expectations

Read more
12 Jan 2016 08:39

Venn Life Sciences Secures Up EUR3.4 Million In Contract Extensions

Read more
8 Jan 2016 16:44

Venn Life Sciences expecting revenues to double

(ShareCast News) - Venn Life Sciences was working to please investors on Friday, revealing its expectations for the year ahead of its full-year results. The AIM-listed drug development services company said revenues for the full year to 31 December were expected to be at least double the previous ye

Read more
8 Jan 2016 07:28

Venn Life Sciences Chairman Resigns, Expects At Least Doubled Revenue

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.